NCT02964078 2026-04-02
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
Clinical Trials
29 trialsNCT05639972 2026-02-27
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Rutgers, The State University of New Jersey
Phase 1/2 Recruiting
NCT05686226 2026-02-27
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Rutgers, The State University of New Jersey
Phase 2 Recruiting
NCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT03260504 2025-12-08
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
University of Washington
Phase 1 Terminated
NCT02306954 2025-03-10
Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer
Providence Health & Services
Phase 2 Active not recruiting
NCT02926053 2024-11-22
TIL Therapy for Metastatic Renal Cell Carcinoma
Herlev Hospital
Phase 1 Completed
NCT00554515 2024-08-28
SELECT
Beth Israel Deaconess Medical Center
Phase 2 Completed
NCT00617799 2023-10-10
Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma
University of Nebraska
Completed
NCT03501381 2023-09-01
High Dose IL 2 and Entinostat in RCC
Hoosier Cancer Research Network
Phase 2 Active not recruiting
NCT01550367 2020-01-02
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
University of Pittsburgh
Phase 1/2 Completed
NCT03935347 2020-01-02
Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy
Roswell Park Cancer Institute
Phase 2 Withdrawn
NCT00853021 2019-06-05
Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00085436 2018-06-26
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00418496 2017-02-20
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00003126 2017-01-04
Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer
Loyola University
Phase 3 Completed
NCT00006022 2015-12-14
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
Virginia Commonwealth University
Phase 1 Completed
NCT00276835 2015-04-10
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer
Northwestern University
Phase EARLY_PHASE1 Completed
NCT01274273 2014-12-02
Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
University of Aarhus
Phase 2 Unknown
NCT00006864 2014-01-09
Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
Case Comprehensive Cancer Center
Phase 4 Completed
NCT00003585 2013-12-10
Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
University of New Mexico
Phase 1/2 Completed
NCT00100906 2013-08-16
Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00002637 2013-06-25
Biological Therapy in Treating Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00278369 2013-05-22
Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer
Northwestern University
Phase EARLY_PHASE1 Completed
NCT00031564 2012-09-27
Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00416429 2012-09-26
Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Centre Leon Berard
Phase 3 Completed
NCT00416871 2012-09-26
Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer
Centre Leon Berard
Phase 3 Completed
NCT00003091 2011-05-12
High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma
Hoag Memorial Hospital Presbyterian
Phase 2 Completed
NCT00002733 2011-05-11
Biological Therapy in Treating Patients With Metastatic Cancer
Hoag Memorial Hospital Presbyterian
Phase 2 Completed